EDINBURGH, UK I January 15, 2025 I Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced ...

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

Researchers sought to determine whether patients who are functional high-risk had a worse prognosis even without having traditional high-risk features.

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...